LOS ANGELES - On Monday, Gilead Sciences Inc. announced its pricing plans for the coronavirus drug Remdesivir, stating it will charge hospitals $3,120 for a patient in the United States with private insurance.“There is no playbook for how to price a new medicine in a pandemic,” Daniel O’ Day, chairman & CEO of Gilead Sciences said in an open letter. “We approached this with the aim of helping as many patients as possible, as quickly as possible and in the most responsible way.”The drugmaker announced the price would be set to $390 per vial for governments of developed countries.